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INTRODuCTION
Colorectal cancer (CRC) is one of the most 
commonly diagnosed cancer in Europe and USA and 
one of the leading causes of cancer death worldwide 
(4,5). EURoCARE project estimates 53,5% relative 
survival of CRC in both sexes (1). Approximately 
30% of all CRCs are diagnosed in the rectum. 
Rectal cancer is the 4th most commonly diagnosed 
malignancy in Bulgaria and represents 7,5% from all 
cancer cases in men and 5% in women. In 2010, the 
newly-diagnosed cases of rectal cancer in men and 
women were 1142 and 685, respectively. An increase 
by 17,6% in the age-standardized incidence rate was 
observed in the last decade in Bulgaria (2).
Although surgery is the leading treatment 
modality for rectal cancer, the multidisciplinary 
management achieves the best clinical results (12).
A number of trials investigate the modalities 
of sequencing, the combination of RT and 
chemotherapy, the RT fractionation regimens and 
the required total dose in addition to surgery, either 
local or radical, contact RT in early rectal cancer and 
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intraoperative RT (IoRT) in locally advanced and 
recurrent rectal cancer (3,14).
Even though large areas of controversies in 
the treatment of rectal cancer still exist, consensus 
guidelines try to help clinicians (8,10,13). In the 
present article, treatment recommendations for rectal 
cancer are defined and radiotherapy indications are 
emphasized. Treatment recommendations are based 
on the recent multidisciplinary ESMo (European 
Society for Medical oncology) and NCCN guidelines.
These recommendations are divided in five 
groups defined by clinical staging (endorectal 
ultrasound - ERUS and magnetic resonance imaging 
- MRI) (13):
1. very early: cT1 sm1/2
2. early: >cT1 sm2-cT2, cT3a/b and no 
mesorectal fascia (MRF) involvement, N0 in 
the proximal/ middle rectum
3. intermediate: >cT3b and no MRF 
involvement, cT4 with limited levator only in 
the proximal/middle rectum or ≥cT3a/b and 
no MRF involvement, N0 in the distal rectum
4. locally advanced: cT3 and MRF involvement, 
cT4, positive lateral lymph nodes
5. locally recurrent.
MRI substaging of T3 tumours is used to 
define different risk groups according to the spread 
from the outermost edge of the tumour to the 
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muscularis propria. The MERCURy trial found out 
a direct association between the extramural depth 
of spread and corresponding pathology results. T3a 
and T3b tumours (tumour spread <5 mm with safe 
circumferential resection margins - CRM) have a 
better prognosis compared with T3c and T3d tumours 
(T3c is >5 mm and <15 mm, T3d is >15 mm) (9).
1. Very early stage: cT1 sm1/2
•• cT1 sm1 with good or moderate differentiation: 
transanal excision performed by transanal 
endoscopic microsurgery (TEMS).
•• cT1 sm2 with good/moderate differentiation: the 
options are TEMS or total mesorectal excision 
(TME). The local RT (e.g. brachytherapy or 
contact therapy) is an alternative to local surgery 
but only in very limited experienced centers. 
In case of higher tumour stage (>pT1sm2) 
or worse prognostic factors (poor differentiation, 
lymphovascular invasion invasion, perineural 
invasion, involved margins) after local excision, 
TME or postoperative chemoradiation (CRT) (with 
inferior results) are recommended.
Local treatment is advised in case of:
•− mobile non-ulcerative exophytic tumour <10 
cm from anal verge
•− tumour <3 cm or less than one-third 
circumference involvement
•− cT1 cN0 cM0
•− well or moderately differentiated tumour
•− no lymphovascular or venous invasion.
Contact x-ray radiotherapy (Papillon treatment) 
is recommended in case of:
•− patients refusing operation and fulfil the 
requirements for local treatment
•− patients with early T1-T2 rectal cancers with 
contraindication for surgery
•− patients with pT1 tumours and R1 resection 
after TEMS
•− patients with pT1> sm2 or pT2 tumours post 
TEMS who are medically contraindicated for 
radical surgery (combined with external CRT). 
With contact RT, local recurrence rates are 10% 
as compared to 1-4% with radical surgery (6,11). Cure 
rate is 90% and mortality one is <1%. No general 
anesthesia is required. Standard treatment is radical 
surgery and contact RT is considered in surgically 
unfit patients.
In case of T1N0 rectal cancers contact RT as 
primary treatment is given in 4 fractions to a total 
dose of 110 Gy in two-week interval (3x30 Gy and 1x 
20 Gy). When tumour persists after the third fraction, 
external beam CRT is recommended because of a 
deeper infiltration.
In case of T2N0 rectal cancers after two 
fractions of 30 Gy contact RT, external beam CRT is 
advised.
In case of R1 resection for low risk pT1 tumours 
application of two fractions of 30 Gy to the excision 
bed is recommended. In case of pT1≥sm2 or pT2 
tumours after local excision initial CRT, contact RT 
boost of 60 Gy in two fractions for the excision bed is 
recommended.
CoNTEM (contact endoscopic microsurgery) 
trials investigate the optimal combination of local 
surgery, contact x-ray RT, CRT or standard TME in 
patients with T1, T2, or early T3 rectal tumours.
Very close follow- up is needed for local 
recurrence and salvage surgery is offered.
2. Early stage: >cT1 sm2-cT2, cT3a/b no MRF 
involvement N0 proximal/middle rectum.
•• >cT1 sm2-cT2: transabdominal (TME) 
surgery with no preoperative treatment is 
recommended.
•• cT3a/b, no MRF involvement, N0 proximal/
middle rectum present with two treatment 
options:
•− primary surgery and  surveillance
•− preoperative short-course RT (SCRT) - 5×5 Gy 
with surgery, which causes more toxicity but 
the local relapse rate is reduced.
Postoperative CRT is required in case of 
positive CRMs, tumour perforation and high risk of 
local recurrence in patients who have not received 
any preoperative CRT.
The long-course CRT includes 50,4 Gy in 28 
fractions with concurrent chemotherapy and it is 
applied either preoperatively (most recommended), 
or postoperatively. 
3. Intermediate stage: >cT3b no MRF 
involvement, cT4 with limited levator only in 
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the proximal/middle rectum or ≥ cT3a/b no 
MRF involvement N0 in the distal rectum. 
•• In these cases (>cT3b without threatened or 
non-involved MRF that is MRI-evaluated) 
preoperative RT followed by TME surgery is 
recommended. CRT and SCRT could be used 
as both show a comparable local recurrence rate 
and late toxicity.
When the tumour is located in the proximal 
rectum >10 cm from the anal verge preoperative CRT 
is recommended only in case of large tumour with 
involvement of the adjacent structures or peritoneal 
reflection. When the tumour in the proximal third 
is at stage ≤T4a treatment is like that for colosigmoid 
cancer.
Surgery timing is different for both preoperative 
approaches. A 2-3-day interval after the end of SCRT 
is recommended. For CRT the delay of surgery is 4-8-
week long. 
When a clinical complete response (cCR) is 
achieved after preoperative CRT, TME is the standard 
treatment. If a local excision is performed with result 
of pCR the standards do not recommend only ‘wait 
and watch’ strategy (in clinical trial settings with 
tight follow-up only). 
Sphincter preservation surgery is recommended 
if the tumour resection could be done with a distal 
margin of one cm. 
•• It is recommended that the patients with no 
preoperative CRT should receive postoperative 
CRT and chemotherapy in case of:
•− involved CRM
•− tumour perforation
•− in every patient with high risk of local recurrence 
(≥pT3b and/or N+) (7).
Postoperative CRT should be followed by 
chemotherapy with either 5-FU or capecitabine for 
a total of 6 postoperative months. The concomitant 
RT to a total dose of 50 Gy in 1,8-2,0 Gy/fraction is 
given either with the first or during the third and 
fourth cycle.
The postoperative CRT compared with the 
preoperative CRT is administered after pathologic 
staging, however, a higher GI toxicity is observed 
and in the surgical field more radio-resistant tumour 
cells are present due to hypoxia.
Postoperative CRT usage is limited because the 
reoperative CRT is the recommended treatment in 
terms of efficacy and toxicity.
The irradiation volumes (clinical target volume) 
need to include:
•− the entire mesorectum with mesorectal nodes. 
In highly located tumours, the lower border is 
4-5 cm distal to the tumour 
•− the presacral nodes along a. rectalis superior up 
to S2 level 
•− internal iliac nodes up to the bifurcation or to 
S2 level
•− the lateral nodes along a. obturatorii when 
the tumour is located below the peritoneal 
reflection with cT3 or  more and positive lymph 
nodes
•− external iliac nodes only when involved or 
the urinary bladder, prostate or female genital 
organs are affected
•− fossae ischiorectales only if there is an 
involvement of the levator muscles and the 
internal and external sphincters 
•− medial inguinal nodes only if massive anal 
sphincter invasion is present.
4. Locally advanced disease: cT3 MRF 
involvement and cT4 and positive ‘lateral 
lymph nodes’ (the drainage lymph nodes 
around a. rectalis media and the obturator 
and internal iliac lymph nodes).
•• In >cT3 MRF-involvement tumours 
preoperative CRT with oral or intravenous 
5-FU is needed followed by surgery.
•• For cT4, close or positive margins, recurrent 
cancer, IoRT boost should be considered. If 
no IoRT is available, brachytherapy boost of 
10-20 Gy could be applied after surgery before 
adjuvant chemotherapy.
5. Locally recurrent disease 
In case of potentially resectable isolated pelvic 
recurrence, surgery and either preoperative or 
postoperative CRT are indicated if no previous 
external beam radiotherapy (EBRT) has been done. 
IoRT and brachytherapy boost are 
recommended in addition to EBRT. In case of 
a previous EBRT, IoRT and brachytherapy are 
recommended. 
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Hyperfractionated accelerated reirradiation 
is well-tolerated in clinical trials and is a treatment 
option, however, not routinely applied because of 
normal tissue tolerance.
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